"The U.S. Food and Drug Administration today approved a new use for Jakafi (ruxolitinib) to treat patients with polycythemia vera, a chronic type of bone marrow disease. Jakafi is the first drug approved by the FDA for this condition.
Kcentra is contraindicated in:
- Patients with known anaphylactic or severe systemic reactions to Kcentra or any components in Kcentra including heparin, Factors II, VII, IX, X, Proteins C and S, Antithrombin III and Human albumin.
- Patients with disseminated intravascular coagulation (DIC).
- Patients with known heparin-induced thrombocytopenia (HIT). Kcentra contains heparin [see DESCRIPTION].
Last reviewed on RxList: 8/12/2013
Additional Kcentra Information
Report Problems to the Food and Drug Administration
Find out what women really need.